Xenon Pharmaceuticals Financial Statements
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals revenue and earnings
In fiscal 2025, Xenon Pharmaceuticals generated $7.5 million in revenue, up 0.0% from fiscal 2024. Xenon Pharmaceuticals reported a net loss of $345.9 million, compared with a loss of $234.3 million a year earlier. Operating margin was -4974.3%.
Diluted earnings per share came in at -$4.36. Over the last 5 fiscal years, XENE's revenue has grown at a -25.3% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.50M | 0 | 0 | 9.43M | 18.44M | 32.17M | 6.83M | — | 311.00K | 1.80M |
| Revenue growth (YoY) | — | — | -100.00% | -48.83% | -42.68% | +371.02% | — | — | -82.75% | -88.43% |
| Operating Expenses | 380.57M | 279.30M | 214.05M | 138.58M | 97.43M | 63.47M | 49.65M | 38.04M | 32.89M | 26.62M |
| Research & Development | 300.94M | 210.39M | 167.51M | 105.77M | 75.46M | 50.52M | 38.84M | 23.63M | 25.57M | 19.83M |
| Operating Income | -373.07M | -279.30M | -214.05M | -129.14M | -78.99M | -31.30M | -42.82M | -38.04M | -32.58M | -24.82M |
| Interest Expense | — | — | — | — | — | 484.00K | 1.43M | 1.39M | — | — |
| Other Income (Expense) | 28.18M | 40.88M | 31.37M | 3.89M | 105.00K | 2.21M | — | — | — | — |
| Pretax Income | -344.89M | -238.42M | -182.69M | -125.25M | -78.89M | -29.09M | -41.62M | -34.52M | — | — |
| Income Tax | 1.02M | -4.09M | -292.00K | 118.00K | -6.00K | -257.00K | -23.00K | -24.00K | — | — |
| Net Income | -345.91M | -234.33M | -182.39M | -125.37M | -78.88M | -28.84M | -41.59M | -34.50M | -30.70M | -23.00M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -4.36 | -3.01 | -2.73 | -2.06 | -1.77 | -0.81 | -1.54 | -1.63 | -1.71 | -1.48 |
| EPS (Diluted) | -4.36 | -3.01 | -2.73 | -2.06 | -1.77 | -0.81 | -1.54 | -1.63 | -1.72 | -1.48 |
| Shares Outstanding (Basic) | 79.25M | 77.89M | 66.89M | 60.54M | 43.63M | 34.54M | 25.94M | 19.43M | 17.99M | 15.49M |
| Shares Outstanding (Diluted) | 79.25M | 77.89M | 66.89M | 60.54M | 43.63M | 34.54M | 25.94M | 19.43M | 18.00M | 15.49M |
| EBITDA | -370.53M | -276.74M | -211.99M | -127.74M | -78.09M | -30.66M | -42.39M | -37.45M | -31.93M | -23.95M |
| Operating Margin | -4974.27% | — | — | -1368.91% | -428.45% | -97.31% | -627.02% | — | -10474.28% | -1376.43% |
| Net Margin | -4612.13% | — | — | -1328.95% | -427.85% | -89.65% | -609.09% | — | -9872.67% | -1275.49% |
This table shows 10 annual periods of Xenon Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow XENE's reporting calendar. What is a income statement?